Dr. Ibrahim Sbeitan
Overview
Ibrahim Sbeitan, MD, specializes in hematology oncology and is board-certified in internal medicine, medical oncology, and hematology by the American Board of Internal Medicine. He practices at UPMC Hillman Cancer Center. Dr. Sbeitan received his medical degree from the University of Jordan School of Medicine and completed his residency at Gundersen Medical Foundation in La Crosse, Wisconsin, followed by a fellowship at the University of Pittsburgh School of Medicine.
Dr. Sbeitan is rated as an Experienced provider by MediFind in the treatment of Melanoma. His top areas of expertise are Chronic Familial Neutropenia, Familial Colorectal Cancer, Lynch Syndrome, and Colorectal Cancer.
His clinical research consists of co-authoring 1 peer reviewed article. MediFind looks at clinical research from the past 15 years.
Insurance
Accepted insurance can change. Please verify directly with the provider.
Accepted insurance plans:
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- POS
- PPO
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE-MEDICAID PLAN
- OTHER COMMERCIAL
- OTHER MEDICARE
- OTHER MEDICARE PART D
- PPO
- HMO
- POS
- PPO
- OTHER MEDICARE
- OTHER MEDICARE PART D
- EPO
- HMO
- PPO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE SNP
- OTHER MEDICARE PART D
- HMO
- POS
- PPO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE SNP
- EPO
- HMO
- PPO
- HMO
- INDEMNITY
- POS
- PPO
- EPO
- POS
- PPO
- OTHER MANAGED MEDICAID
- OTHER MEDICAID
- STATE MEDICAID
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- MEDICARE-MEDICAID PLAN
- OTHER MEDICARE PART D
- PPO
- HMO
- MANAGED MEDICAID PLAN
- OTHER COMMERCIAL
- EPO
- HMO
- POS
- PPO
- EPO
- PPO
- EPO
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- MEDICARE-MEDICAID PLAN
- OTHER MEDICARE
- OTHER MEDICARE PART D
Locations
337 Somerset Street, Johnstown, PA 15901
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
University Of Pittsburgh Physicians
Jason Luke is a Hematologist Oncology specialist and an Oncologist in Pittsburgh, Pennsylvania. Dr. Luke is rated as a Distinguished provider by MediFind in the treatment of Melanoma. His top areas of expertise are Melanoma, Metastatic Uveal Melanoma, Uveal Melanoma, Melanoma of the Eye, and Liver Embolization.
UPMC Hillman Cancer Center
John M. Kirkwood, MD, is a professor of medicine, dermatology, and clinical and translational science at the University of Pittsburgh School of Medicine and the Clinical and Translational Science Institute at the University of Pittsburgh. Dr. Kirkwood directs the Melanoma Center at UPMC Hillman Cancer Center and specializes in melanoma research and the prevention and early detection of melanoma, as well as the treatment of advanced disease and adjuvant therapy of resectable disease. Dr. Kirkwood is rated as a Distinguished provider by MediFind in the treatment of Melanoma. His top areas of expertise are Melanoma, Melanoma of the Eye, Metastatic Uveal Melanoma, and Uveal Melanoma.
UPMC Hillman Cancer Center
Yana G. Najjar, MD is a translational investigator and cutaneous oncologist at UPMC Hillman Cancer Center, where she also is an associate professor of medicine and Director of the Clinical and Translational Research Center. Dr. Najjar specializes in early phase clinical trials and in the treatment of advanced melanoma. Her research focusing on immunotherapy resistant melanoma and rare melanoma subtypes. She has developed multiple investigator-initiated trials that aim to remodel melanoma tumor cell metabolism and hypoxia in the tumor microenvironment to overcome mechanisms of resistance to immunotherapy. Her lab is focused on various correlative analyses from investigator-initiated trials. Dr. Najjar's research is funded by the NIH, the Department of Defense, and the Melanoma Research Alliance. Dr. Najjar is rated as a Distinguished provider by MediFind in the treatment of Melanoma. Her top areas of expertise are Melanoma, Melanoma of the Eye, Metastatic Uveal Melanoma, Renal Cell Carcinoma (RCC), and Gamma Knife Radiosurgery.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Distinguished
- Chronic Familial NeutropeniaDr. Sbeitan isDistinguished. Learn about Chronic Familial Neutropenia.
- Colorectal CancerDr. Sbeitan isDistinguished. Learn about Colorectal Cancer.
- Familial Colorectal CancerDr. Sbeitan isDistinguished. Learn about Familial Colorectal Cancer.
- Lynch SyndromeDr. Sbeitan isDistinguished. Learn about Lynch Syndrome.
- Paget Disease of the BreastDr. Sbeitan isDistinguished. Learn about Paget Disease of the Breast.
- Advanced
- Adult Soft Tissue SarcomaDr. Sbeitan isAdvanced. Learn about Adult Soft Tissue Sarcoma.
- AgranulocytosisDr. Sbeitan isAdvanced. Learn about Agranulocytosis.
- ALK-Positive Non-Small Cell Lung Cancer
- AnemiaDr. Sbeitan isAdvanced. Learn about Anemia.
- AngiosarcomaDr. Sbeitan isAdvanced. Learn about Angiosarcoma.
- Atypical Hemolytic Uremic Syndrome (aHUS)
- Experienced
- Acute Eosinophilic PneumoniaDr. Sbeitan isExperienced. Learn about Acute Eosinophilic Pneumonia.
- Acute Mountain SicknessDr. Sbeitan isExperienced. Learn about Acute Mountain Sickness.
- Acute Myeloblastic Leukemia with Maturation
- Acute Myeloblastic Leukemia without Maturation
- Acute Myeloid Leukemia (AML)Dr. Sbeitan isExperienced. Learn about Acute Myeloid Leukemia (AML).
- Adrenal CancerDr. Sbeitan isExperienced. Learn about Adrenal Cancer.